This company listing is no longer active
OncoSec Medical (ONCS.Q) Stock Overview
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ONCS.Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
OncoSec Medical Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.13 |
| 52 Week High | US$18.99 |
| 52 Week Low | US$0.11 |
| Beta | 2 |
| 1 Month Change | -68.98% |
| 3 Month Change | -94.83% |
| 1 Year Change | -99.25% |
| 3 Year Change | -99.70% |
| 5 Year Change | -99.95% |
| Change since IPO | -98.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONCS.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -36.5% | -2.4% | 0.7% |
| 1Y | -99.3% | 35.9% | 20.6% |
Return vs Industry: ONCS.Q underperformed the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: ONCS.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| ONCS.Q volatility | |
|---|---|
| ONCS.Q Average Weekly Movement | 28.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ONCS.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ONCS.Q's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 41 | n/a | oncosec.com |
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company’s product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma.
OncoSec Medical Incorporated Fundamentals Summary
| ONCS.Q fundamental statistics | |
|---|---|
| Market cap | US$804.96k |
| Earnings (TTM) | -US$29.39m |
| Revenue (TTM) | n/a |
Is ONCS.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCS.Q income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.39m |
| Earnings | -US$29.39m |
Last Reported Earnings
Jan 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -132.9% |
How did ONCS.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/28 07:36 |
| End of Day Share Price | 2023/06/28 00:00 |
| Earnings | 2023/01/31 |
| Annual Earnings | 2022/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OncoSec Medical Incorporated is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Thomas Shrader | BTIG |
| Raghuram Selvaraju | H.C. Wainwright & Co. |